08 May, 2017
About 230,381 shares traded or 240.88% up from the average. It has outperformed by 42.45% the S&P500. We have $3.70 PT which if reached, will make NASDAQ:AGEN worth $24.54M less. (PRTK) stake by 51.29% reported in 2016Q4 SEC filing. The shares were sold at an average price of $15.09, for a total transaction of $46,869.54. Senzar Asset Management Limited owns 0.51% invested in Paratek Pharmaceuticals Inc (NASDAQ:PRTK) for 124,519 shares. Meredith Corp now has $2.51B valuation. The last session's volume of 7.20 million shares was lower than its average volume of 9.89 million shares. Zacks Investment Research lowered Paratek Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, April 21st. Therefore 86% are positive. The stock of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) earned "Hold" rating by Zacks on Saturday, August 22. Blackrock Fund Advsr has invested 0% in Paratek Pharmaceuticals Inc (NASDAQ:PRTK). The company was initiated on Thursday, July 23 by Gabelli. Zacks downgraded the stock to "Hold" rating in Saturday, August 8 report.
A number of brokerages have recently issued reports on PRTK. As per Friday, June 17, the company rating was maintained by Ladenburg Thalmann.
10/27/2016 - Leerink Swann began new coverage on Paratek Pharmaceuticals, Inc. giving the company a "outperform" rating. Four analysts rating the company a strong buy, three analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $3.80. Wedbush maintained it with "Outperform" rating and $34 target in Tuesday, April 4 report. The stock has "Hold" rating by Zacks on Tuesday, September 22.
Investors sentiment decreased to 1.22 in Q4 2016. 0 analysts call it Underweight, while 1 think it is Overweight.
The pharmaceutical company posted revenue of $18,000 in the period. 14 funds opened positions while 25 raised stakes. Bnp Paribas Arbitrage Sa reported 0% stake. HC Wainwright upped their price objective on shares of Paratek Pharmaceuticals from $33.00 to $36.00 and gave the stock a "buy" rating in a research report on Tuesday, April 11th. Goldman Sachs Group stated it has 0% in Paratek Pharmaceuticals Inc (NASDAQ:PRTK).
Several analysts have recently weighed in on the stock. Grt Prns Ltd Liability reported 27,339 shares. Credit Suisse Ag reported 13,257 shares or 0% of all its holdings. Market Capitalization if basically the market value of the company's shares outstanding. The firm earned $0.02 million during the quarter. Next Grp reported 73 shares. Weiss Multi holds 0.01% or 10,000 shares.
Yet another important factor while evaluating a good buy/sell decision for Paratek Pharmaceuticals, Inc. The company has market cap of $69.29 million. The Firm is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. It now has negative earnings. The Company's product candidates are the antibacterials omadacycline and sarecycline.
Since February 14, 2017, it had 2 buys, and 0 sales for $60.33 million activity. The shares were sold at an average price of $15.09, for a total value of $75,450.00. (PRTK) has the trading volume of 4.18 Million shares with the average trading volume of 996440 shares. A P/B ratio of less than 1.0 can indicate that a stock is undervalued, while a ratio of greater than 1.0 may indicate that a stock is overvalued. (NASDAQ:EBAY) stake by 285,000 shares to 580,000 valued at $17.22M in 2016Q4. Another trade for 19,965 shares valued at $1.22M was sold by PARKER SIR JOHN. Vanguard Intl Equity Index F (VWO) was raised too.
Investors sentiment decreased to 1.22 in Q4 2016. Its down 0.33, from 1.55 in 2016Q3. It improved, as 18 investors sold CUK shares while 43 reduced holdings. 22 funds opened positions while 32 raised stakes. Wells Fargo & Company MN now owns 8,005 shares of the specialty pharmaceutical company's stock valued at $104,000 after buying an additional 5,305 shares in the last quarter. Goldman Sachs Inc reported 0% of its portfolio in Systemax Inc. Northwestern Mutual Wealth Mgmt holds 0% in Carnival plc (ADR) (NYSE:CUK) or 471 shares. Tekla Ltd reported 762,581 shares. Morgan Stanley owns 33,466 shares. Allianz Asset Ag owns 245,085 shares or 0% of their United States portfolio. Insiders own 2.00% of the company's stock. Rhumbline Advisers reported 17,443 shares.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
